We are thrilled to welcome Gerald Moeller as new member of our Board of Directors

march 14, 2023

We are thrilled to welcome Gerald Moeller as new member of our Board of Directors.

Dr. Gerald Moeller has more than 40 years of management experience in the diagnostic, pharmaceutical and MedTech industries.

From 1975-1998, Dr. Moeller held several senior level positions in Germany, Japan, USA and the Netherlands with Boehringer Mannheim. In 1995 he became CEO of the worldwide Boehringer Mannheim Group. Following the sale of Boehringer Mannheim Group to Roche in 1998, Dr. Moeller was named Head of Global Development and Strategic Marketing Pharmaceuticals, as well as a member of Roche’s Executive Committee. Dr. Moeller left Roche in December 1998.

Dr. Moeller served on the board of several BioTech companies in Germany, France, UK and USA. Definiens, Illumina, Powderject, Morphosys and BRAHMS are examples. As Chairman of the Board he was actively involved in the sale of BRAHMS AG to ThermoFisher Scientific Inc. He was also an Investment Advisor to HBM Partners, Zug/Switzerland.

Dr Möller cofounded Adrenomed AG, a Biopharmaceutical company, served as Vice Chairman, CEO and now again as member of the Board.
From 2003 to 2016 he was Chairman of FIND (Foundation of New Innovative Diagnostics).

Today he serves on the Board of 4Sigma Ltd, Sphingotec GmbH, 4teen4 Pharmaceuticals GmbH, Diadem DX SRL and IOmx Therapeutics AG.

Dr Möller studied Physical Chemistry at University of Kiel / Germany.

About Aignostics

Aignostics specializes in AI-powered pathology, uniquely combining proprietary technology, its pathologist network, and comprehensive access to key data modalities to build bespoke AI models for its global pharma and biotech client base. These AI models can deliver valuable insights into disease biology from tissue samples, such as novel biomarkers and drug response characteristics.

Aignostics formally started in 2018 in the Digital Health Accelerator program of the Berlin Institute of Health (BIH), based on joint research by Charité – Universitätsmedizin Berlin, one of Europe’s largest university hospitals, led by Prof. Frederick Klauschen, and TU Berlin, led by Prof. Klaus-Robert Müller. In early 2020, Aignostics was spun-out of Charité. To date, Aignostics has raised close to €20million in funding from leading VC investors and has offices in Berlin, Germany, and Boston, U.S.


Aignostics GmbH
Viktor Matyas, CEO

Email: info@aignostics.com

Media contact:
MC Services AG
Kaja Skorka, Dr. Regina Lutz
Phone: +49 89-210 2280
Email: aignostics@mc-services.eu